Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Preferred Stock Liabilities (2023 - 2024)

BioAge Labs' Preferred Stock Liabilities history spans 2 years, with the latest figure at $342.8 million for Q2 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $342.8 million in Q2 2024 year-over-year; TTM through Jun 2024 was $342.8 million, a N/A change, with the full-year FY2023 number at $132.7 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $342.8 million in Q2 2024 for BioAge Labs, roughly flat from $342.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for BIOA hit a ceiling of $342.8 million in Q1 2024 and a floor of $132.7 million in Q4 2023.